NEW YORK (TheStreet) -- Stay here all day for live coverage from the second and final day of the BIO CEO & Investor Conference.
The two-day conference, put on by BIO, the biotech industry's main lobbying group, typically spotlights small-cap biotech companies that are often shut out of investor conferences run by large investment banks.
Pfizer's (PFE) Dr. Mikael Dolsten, Head of Worldwide Research, kicks off the BIO conference this morning with a breakfast "fireside chat" at 8 am ET.
Around the same time, Idenix Pharmaceuticals (IDIX), CEO Ron Renaud will be speaking on CNBC. Given that he's pre-booked for the network likely means he won't be announcing the takeout deal investors have been pining for, but his comments on future plans for his company's hepatitis C drugs will be closely followed. Renaud presents at the BIO conference later this morning. Other noteworthy presenting companies Tuesday include Delcath Systems (DCTH), Keryx Pharmaceuticals (KERX), Oncothyreon (ONTY), Acorda Therapeutics (ACOR) and Human Genome Sciences (HGSI). Gilead Sciences' (GILD) President John Milligan will also be featured in a "fireside chat" this afternoon. I have one-on-one meetings today with Acorda, BioMarin Pharmaceuticals (BMRN) and Affymax (AFFY) To make it easier to follow the news, debate and conversations expected to flow from this years BIO CEO confab, feel free to check in periodically to this live blog that will aggregate all tweets using the #BIOCEO2012 hashtag. An archive of tweets and comments from Day One of the BIO CEO conference is still available. --Written by Adam Feuerstein in Boston.>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
